Saturday 17 October 2026
Export SNOA’s income statement to Excel — free account
Sonoma Pharmaceuticals, Inc.
SNOA Healthcare Drug Manufacturers Specialty & Generic
Sonoma Pharmaceuticals, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $19.5 million, up 36.7% from fiscal 2025. In the quarter to June 2026, revenue grew 59.6%, EPS grew 88.2% and free cash flow grew 69.3%, each against the same quarter a year earlier.
1.13
0.02
−1.74%
Follow SNOA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.22 | 0.18 | 0.35 | 0.38 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(7.29) | (6.91) | (8.16) | (10.06) | |
P/B ratio |
0.72 | 1.16 | 1.82 | 1.69 | |
Price to Tangible BV |
0.72 | 1.16 | 1.82 | 1.69 | |
EV/Sales |
(0.02) | 0.07 | 0.21 | 0.20 | |
EV/EBITDA |
0.40 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
0.20 | (0.33) | (1.07) | (1.58) | |
EV/FCF |
0.19 | (0.31) | (1.01) | (1.47) | |
Quick Ratio |
1.56 | 1.02 | 1.17 | 1.33 | |
Current Ratio |
2.99 | 2.50 | 2.88 | 2.89 | |
Net Debt/EBITDA |
667.25 | 7.54 | 3.98 | 10.08 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.34 | 1.41 | 1.30 | 1.23 | |
Operating CF/Net income |
1.97 | 0.89 | 0.93 | 1.19 | |
Capex/Depreciation |
(0.06) | (0.88) | (1.38) | (0.28) | |
Research and Development Expense of Revenue |
9.32% | 9.80% | 12.81% | 10.26% | |
Selling, General and Administrative Expense of Revenue |
31.53% | 35.73% | 40.72% | 33.58% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.91% | 2.43% | 0.55% | 0.70% | |
Graham Net Nets |
1.01 | 0.34 | 0.31 | 0.38 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(99.19%) | (88.73%) | (56.04%) | (56.44%) | |
Free Cash Flow Yield |
(56.12%) | (115.00%) | (59.64%) | (36.72%) | |
Revenue per Share |
1.67 | 3.30 | 2.54 | 3.40 | |
Operating CF per Share |
(0.17) | (0.31) | (0.45) | (0.39) | |
Capex per Share |
0.00 | (0.02) | (0.03) | (0.01) | |
Free Cash Flow per Share |
(0.17) | (0.33) | (0.47) | (0.39) | |
Cash per Share |
1.39 | 1.42 | 1.50 | 1.84 | |
Shareholders Equity per Share |
1.71 | 1.84 | 2.00 | 2.30 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.71 | 1.84 | 2.00 | 2.30 | |
Free Cash Flow |
(0.65) | (0.55) | (0.81) | (0.64) | |
Working Capital |
10.82 | 7.27 | 7.93 | 8.18 | |
Capital Expenditures |
0.00 | (0.03) | (0.05) | (0.01) | |
Net Current Asset Value |
4.76 | 1.24 | 1.95 | 2.43 | |
EV/EBIT |
0.36 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.89 | 2.38 | 2.39 | 2.93 | |
Average Payables |
2.12 | 1.44 | 1.52 | 1.09 | |
Average Inventory |
3.79 | 3.28 | 3.42 | 3.24 | |
Average Assets |
16.35 | 13.83 | 13.65 | 13.77 | |
Average Common Equity |
5.33 | 3.75 | 4.15 | 4.57 |
Columns are period end dates